Drug application
SER-AP-ES (HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, RESERPINE)
Drugs@FDA NDA 012193 · NOVARTIS
Key facts
| Drug name | SER-AP-ES |
|---|---|
| Active ingredients | HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE, RESERPINE |
| Application type | NDA |
| Application number | 012193 |
| Company | NOVARTIS |
| Dosage forms | TABLET, ORAL |
| Strength | 25MG;15MG;0.1MG |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 4 - New Combination |
| Latest submission status date | Feb 11, 1960 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.